The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.

PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-41BBL fusion protein, host-cells expressing the PD1-41BBL fusion protein and methods of use thereof.

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.

[Problem] Provided are a production method for a multi-input/multi-output-type genetic switch or a transcription factor, and a multi-input/multi-output-type genetic switch or a transcription factor. [Solving Means] The inventors of the present invention have completed a production method for a multi-input/multi-output-type genetic switch or a transcription factor, essentially including the steps of “fusing two or more transcription factor genes to each other” and “introducing mutations into the fusion-type transcription factor gene,” and have further succeeded in obtaining a multi-input/multi-output-type genetic switch or a transcription factor by the method.

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells; chimeric antigen receptors (CARs); immune cells; pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

Provided herein are compounds comprising cyclic cell penetrating peptides and antisense compounds. Also provided herein are methods of modulating splicing, inhibiting or regulating translation, mediating degradation, blocking expansions of nucleotide repeats, and treating disease using the aforementioned compounds.

The invention relates to a method for identifying compounds useful for the treatment of cancer based on assessing the ability of the compound to modulate the interaction between the AIF protein and the CHCHD4 protein.

The invention relates to a method for identifying compounds useful for the treatment of cancer based on assessing the ability of the compound to modulate the interaction between the AIF protein and the CHCHD4 protein.

This disclosure relates to coronavirus vaccines and uses thereof. In one aspect, the disclosure provides a nucleic acid vaccine, comprising a sequence encoding a spike protein or fragment thereof derived from a coronavirus.

In order to develop tools and methods useful in a variety of applications, including the research and development of medical treatments which involve the modification of collagen protein and use of the same, the present invention provides a modified collagen protein expressed in a transformed cell and capable of forming collagen fibers outside of the cell, wherein the transformation is performed by introducing, into the cell, polynucleotides coding the modified collagen protein.